AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/17/2025 07:15 PDT] AXIM Expected to Trade Up After Bullish Patterns Develop
• [06/09/2025 11:07 PDT] AXIM Biotechnologies, Inc (OTC:AXIM), Down By 100% ($0.01) From $0.007 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/09/2025 11:07 PDT] AXIM Biotechnologies, Inc (OTC:AXIM), Down By 100% ($0.01) From $0.007 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/09/2025 07:18 PDT] AXIM Expected to Trade Up After Bullish Patterns Develop
• [05/27/2025 07:24 PDT] AXIM Expected to Trade Down After Bearish Patterns Develop
• [05/23/2025 07:49 PDT] AXIM Expected to Trade Down After Bearish Patterns Develop
• [05/16/2025 07:14 PDT] AXIM Expected to Trade Up After Bullish Patterns Develop